Company: BOLT
Filing Date: 2025-04-16
Form Type: PRE 14A
Source: 0000950170-25-054405
Chunk: 24

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-04-16
Form: PRE 14A
Chunk 24
---
 succession plans for our executive officers.

After taking into consideration the six factors prescribed by the SEC and Nasdaq, the compensation committee engaged Aon plc, or Radford, as compensation consultants. The compensation committee requested that Radford:

evaluate the efficacy of the Company’s existing compensation strategy and practices in supporting and reinforcing the Company’s long-term strategic goals; and

assist in refining the Company’s compensation strategy and in developing and implementing an executive compensation program to execute that strategy.

As part of its engagement, the compensation committee requested that Radford develop a comparative group of companies and perform analyses of competitive performance and compensation levels for that group. At the request of the compensation committee, Radford also conducted individual interviews with members of the compensation committee and senior management to learn more about the Company’s business operations and strategy, key performance metrics and strategic goals, as well as the labor markets in which the Company competes. Radford ultimately developed recommendations that were presented to the compensation committee for its consideration. Following an active dialogue with Radford, the compensation committee approved the recommendations of Radford.

<div align='center'>14</div>

Nominating and Corporate Governance Committee

Our nominating and corporate governance committee consists of Laura Berner, Jakob Dupont, M.D. and Nicole Onetto, M.D. The chairperson of our nominating and corporate governance committee is Laura Berner. Our Board has determined that each member of the nominating and corporate governance committee is independent under the listing standards of Nasdaq. Specific responsibilities of our nominating and corporate governance committee include:

identifying and evaluating candidates, including the nomination of incumbent directors for reelection and nominees recommended by stockholders, to serve on our Board;

considering and making recommendations to our Board regarding the composition and chairmanship of the committees of our Board;

reviewing with our Chief Executive Officer the plans for succession to the offices of our executive officers and make recommendations to our Board with respect to the selection of appropriate individuals to succeed to these positions;

developing and making recommendations to our Board regarding corporate governance guidelines and matters; and

overseeing periodic evaluations of the Board’ performance, including committees of the Board.

Our nominating and corporate governance committee believes that candidates for director should have certain minimum qualifications, including the ability to read and understand basic financial statements, being over 21 years of age and having the highest personal integrity and ethics. The nominating and corporate governance committee also intends to consider such factors as possessing relevant expertise upon which to be able to offer advice and guidance to management, having sufficient time to